Website: www.ijhsr.org
Case Report ISSN: 2249-9571

Cryptococcal Meningitis and Its Optimal Antifungal Therapy

Jimmer Joe¹, Shravan Jayachnadran¹, A. Priya², K. Arun Chander Yadav³

¹Clinical Pharmacist, Apollo Children's Hospital, Chennai, Tamil Nadu, India.

²Junior Executive, Apollo Children's Hospital, Chennai, Tamil Nadu, India.

³Consultant Clinical Pharmacologist, Apollo Children's Hospital, Chennai, Tamil Nadu, India.

Corresponding Author: K. Arun Chander Yadav

ABSTRACT

Cryptococcal meningitis is the major life threatening opportunistic infection and is caused by Cryptococcus neoformans. Severe headache and with or without fever is the characteristic feature in patients with cryptococcal meningitis. Headache is seen in > 75% while Fever is seen in only 65% of the patients. For the diagnosis of cryptococcal infection neuroimaging of the brain, India ink, cerebrospinal fluid (CSF) culture is considered. We report a case of cryptococcal meningitis who's cryptococcal antigen testing was positive and India ink examination showed the cells resembling cryptococcus and he was treated with antifungal drugs mainly the combination therapy showed better outcome.

Key Words: Cryptococcal meningitis, Amphotericin B, Cerebrospinal fluid (CSF)

INTRODUCTION

Cryptococcosis is a subacute or chronic meningeal infection caused by the yeast-like fungus Cryptococcus neoformans. It is reproduced by budding and is an encapsulated, yeast-like fungus. It is a saprophyte in nature, with a world-wide distribution rather than any defined endemic Because the organism omnipresence it is presumed that exposure to C.neoformans is common. Headache and fever are the most common symptoms associated with cryptococcal meningitis. Cryptococcal meningitis is unrecognized for several days and weeks and may manifest as pyrexia of unknown origin. [2] Nausea, vomiting, and neck stiffness are the less common symptoms and cryptococcal meningitis are asymptomatic in some patients. [3,4,1]

Cryptococcal infection of the central nervous system is nearly always detected by abnormalities in the cerebrospinal fluid. Cryptococcal meningitis may cause

progressive visual disturbances such as decreased visual acuity, increased blind spot, papilloedema, optic atrophy. With the enhancement of the relevance ratio and recognition of its life-threatening effect, more and more clinicians' attention should be needed for cryptococcal meningitis. According to the official statistics approximately one million new cases each year worldwide and the lethality is more than 50 percent [5,6]. However the azole antifungal group has shown excellent results in the treatment of cryptococcal meningitis. Combination of flucytosine amphotericin B is the best present induction therapy for Cryptococcal infection.

CASE REPORT

The patient was a 11year-old who was previously well and first presented to a private pediatrician with a complaint of occasional headache and they suspected case of? Meningitic sequelae with OCT (Optical coherence tomography) showing

increased RNFL (Retinal nerve fiber layer) and early thinning of Ganglion cell layer for Paediatric neurology opinion and further management.

Child presented with gradual painless loss of vision initially with blurring vision. increasing scotoma and of progressively worsening loss of vision. Mild perception of light in right eye present. Left eye – absent. History of ?seizures preceded by aura – past 4 days, bilateral upper limb jerky movements with awareness surroundings, lasting for few seconds, post ictal drowsiness lasts for 10 minutes. Currently 3-4 episodes per day. Was seizure free for 25 days prior, on good compliance with anti-epileptic drugs.

The child was admitted for the above complaints. On admission , under aseptic precautions, lumbar puncture was done and CSF was sent for analysis - cell count, biochemistry, cultures, India ink stain and Xpert MTB on consultation with Infectious disease specialist.

CSF cell counts: **WBC** 6.21 10³/mm³, RBC-3400 cells/mm³, Glucose -57, Protein - 35.6g/dl, Chloride -125mmol/l. No AFB seen on AFB (acid-fast bacillus) stain, Gene Xpert MTB - negative.India ink stain for Cryptococcus revealed moderate capsulated budding yeast like cells resembling cryptococcus and cryptococcal antigen testing was positive. Infectious disease specialist opined as non-responsive (Amphotericin given for 7 days in previous hospital admission) cryptococcal meningitis in apparently immunocompetent host and advises re-introduction with Liposomal amphotericin B and 5-flucytosine for 4 weeks with regular monitoring of serum K and creatinine. Primary immunodeficiency workup was done which was unremarkable. Ophthal opinion was sought on the advice of I.D specialist: Fundus - Disc edema + pallor + tortuousity of vessels + media clear,ocular movements full, visual axis clear. No evidence of chorioretinitis or vitritis noted. Opined as Disc edema due to secondary ICT changes. Advised for VEP (visual evoked potential) of both eyes.

Due to the need of long term iv medication, PICC (peripherally inserted central catheter) line was inserted in the right cubital fossa on under aseptic precautions. Pre and post procedure were normal and functioning well.

The child was treated with oral antiepileptics and antifungals. There was a mild decreased in potassium levels from 5.meq/l to 3.4meq/l for which he was given oral potassium supplements with stat dose of i.m MGSO4. He had nausea with intermittent abdominal pain for which he was given oral emeset and Liver function tests were done on the advice of Infectious disease specialist and his Ambisome dose was re-adjusted (100->75mg iv OD).

He had mild painful swelling in his lower lumbar spine, for which USG at lumbar puncture site was done - which revealed focal subcutaneous soft tissue inflammation seen at the lumbar puncture site. No collection present. Hence he was advised to start on oral amoxicillin.

Infectious disease consultant also advised for repeat cell count, biochemistry, fungal culture (only) and India ink stain to check for response to treatment of meningitis. Parents were counselled for long term therapy with anti-fungal and he is being discharged on the following advice. He is advised for ophthalmic assessment and to reassess his visual status. Regular monitoring of serum K, Cr, mg is required to manage toxicity.

DISCUSSION

The majority of the patients with cryptococcal meningitis get better with adequate therapy. Morbidity is unusual while mortality is seen in about 10% of the cases.

Headache, fever, neck pain are the nonspecific clinical manifestations Cryptococcal meningitis. In this patient he suffering with fever, headache was occasional and also have vision related problems. Initially they were suspecting meningitis, further India ink stain for Cryptococcus revealed that moderate capsulated budding yeast like cells resembling cryptococcus and Cryptococcal antigen testing was positive. It is important to diagnosis early of cryptococcal infection for better outcomes. Usually cryptococcal infection has been diagnosed by India ink microscopy on cerebrospinal fluid (CSF), culture or latex agglutination for cryptococcal antigenaemia. [7]

Amphotericin B is the important drug of choice (DOC) for initial therapy in CNS cryptococcosis. It is used based on either condition used alone or in with combination flucvtosine. **Studies** shows that compare to intravenous or oral fluconazole, Amphotericin B often leads to clinical improvement more rapidly and has a rapid onset of action. Monitor renal function carefully throughout its administration, because amphotericin B is nephrotoxic. However Amphotericin B administered over a 6- to 8-hour period have more chances of nephrotoxicity, instead of that administered as a continuous infusion over 24 hours have significantly appears to nephrotoxicity. For this patient initially infectious disease specialist opined as nonresponsive (Amphotericin given for 7 days in previous hospital admission) cryptococcal meningitis in apparently immunocompetent host and advise to start Liposomal amphotericin B.

Other preparations of amphotericin B include amphotericin B cholesteryl (Amphotec), complex liposomal amphotericin B (AmBisome), amphotericin lipid complex (Abelcet). colloidal amphotericin В dispersion (Amphocin). As they all cost much more, It remains unclear if these alternative forms of amphotericin B are superior to standard nonlipid amphotericin B. The preparations may have an advantage in sparing renal function compare with amphotericin B desoxycholate, but they may be associated with higher relapse rates. Elevations in serum creatinine and BUN level associated with amphotericin B usually return to normal after therapy is completed. Amphotericin B administering as a continuous drip over 24 hours reduces the frequency and severity of renal toxicity. [8]

For this patient after he was confirmed with cryptococcal meningitis from the side of infection control team he started to receive the intravenous Liposomal amphotericin B 100 mg OD and tablet 5-flucytosine 500 mg thrice a day for 4 weeks with regular monitoring of serum K and creatinine. Electrolyte disturbances are common in amphotericin therapy. In this patient during hospital stay there was a mild decrease in potassium level and it was corrected by potassium supplement and readjusted the dose of inj.amphotericinB 75 mg OD.

Flucytosine should be administered in conjunction with amphotericin B since it is unreliable if used alone, and resistance develops rapidly in cryptococcal disease. Data on the use of fluconazole plus flucytosine are limited because of this combination have less effectiveness but amphotericin B plus flucytosine are more effective and for the better outcome patient was advised to receive long term therapy with antifungal drugs and monitoring of Serum K, Creatinine, Mg levels once in 2-3 days.

CONCLUSION

In conclusion, cryptococcal meningitis is the most opportunistic, fungal infection of the nervous system. Early diagnosis and proactive antifungal therapy may save the lives of the patients. Our patient showed a good clinical and laboratory response to the combination therapy of intravenous Liposomal amphotericin B and oral flucytosine.

ACKNOWLEDGEMENT

We would like to express our sincere gratitude towards the Department of Neurology (Pediatrics) for helping us by providing all the data necessary to incorporate in this case report.

Conflict of Interest: None Declared

Source of Funding: No funding sources

Ethical Approval: Not required

REFERENCES

- Diamond RD. Cryptococcus neoformans.
 In: Mandell, Duglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone; 1995.
- Gelfand JA, Wolff SM. Fever of unknown origin. In: Mandell, Douglas and Bennett's principles and practice of infectious diseases. 4th ed. New York: Churchill Livingstone;1995.
- 3. Sarosi GA, Parker JD, Doto IL, et al. Amphotericin B in cryptococcal meningitis: long-term results of treatment. Ann Intern Med 1969; 71: 1079-87.
- 4. Sabetta JR, Adriole VT. Cryptococcal infection of the central nervous system. Med Clin North Am1985; 69: 333-44.
- 5. Lin YY, Shiau S and Fang CT. Risk factors for invasive Cryptococcus neoformans diseases: a case-control study. PLoS One 2015; 10: e0119090.

- Panackal AA, Wuest SC, Lin YC, Wu T, Zhang N, Kosa P, Komori M, Blake A, Browne SK, Rosen LB, Hagen F, Meis J, Levitz SM, Quezado M, Hammoud D, Bennett JE, Bielekova B and Williamson PR. Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis. PLoS Pathog 2015; 11: e1004884.
- 7. Bongomin F, Gago S. Oladele RO, Denning DW. HIV –Associated Cryptococcal Disease in Resource-Limited Setting: A case for Prevention is better than Cure. Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision. J Fungi 2017;3:57.
- 8. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001; 322(7286):579-82.

How to cite this article: Joe J, Jayachnadran S, A. Priya et.al. Cryptococcal meningitis and its optimal antifungal therapy. *Int J Health Sci Res.* 2021; 11(7): 164-167. DOI: https://doi.org/10.52403/ijhsr.20210723
